Publications
Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
BCMA-targeted CAR T cell therapy can effectively induce disease remission in refractory lupus nephritis
Ann Rheum Dis 2025;0:1−9
Hu et al. report that anti-BCMA only CAR T cell can help LN patients safely and effectively, indicating its potential to be a feasible therapeutic strategy in treating autoimmune diseases with abnormal humoral immune responses.
Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus
N Engl J Med. 2022;387(10):894–904 doi: 10.1056/NEJMoa2118025
Phase 2 study, in patients with systemic lupus erythematosus, shows that litifilimab is associated with a greater reduction from baseline in the number of swollen and tender joints than placebo, over a period of 24 weeks.
Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus
N Engl J Med. 2022;387(4):321–331 doi: 10.1056/NEJMoa2118024
Phase II study, in patients with active cutaneous lupus erythematosus, shows that litifilimab improved scores on a measure of skin disease activity, over 16 weeks, compared to placebo.